

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 May 2018 (03.05.2018)



(10) International Publication Number
WO 2018/077630 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) A61K 31/497 (2006.01)
A61K 31/4738 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2017/076191

(22) International Filing Date:

13 October 2017 (13.10.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/411,799 24 October 2016 (24.10.2016) US
62/435,159 16 December 2016 (16.12.2016) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85
Södertälje (SE).

(72) Inventors: **SCOTT, James, Stewart**; AstraZeneca Darwin Building, Cambridge Science Park, Milton Road Cambridge CB4 0WG (GB). **BARLAAM, Bernard, Christophe**; AstraZeneca, Darwin Building Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WG (GB). **YANG, Bin**; AstraZeneca 35 Gatehouse Drive, Waltham, MA 02451 (US). **MOSS, Thomas, Andrew**; AstraZeneca, Darwin Building Darwin Building,

Cambridge Science Park, Milton Road Cambridgeshire CB4 0WG (GB). **HUGHES, Samantha, Jayne**; AstraZeneca Darwin Building, Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WG (GB). **NISSINK, Johannes, Wilhelmus, Maria**; AstraZeneca, Darwin Building Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WG (GB). **O'DONOVAN, Daniel, Hillebrand**; AstraZeneca Darwin Building, Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WG (GB).

(74) Agent: **COOK, Andrew, James**; AstraZeneca Milstein Building, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(54) Title: 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER





Figure 1: X-Ray Powder Diffraction Pattern for Form A of N-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine



(57) Abstract: The specification relates to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.

WO 2018/077630 A1

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*